Lupin Gears For Europe Specialty Push With Orphan NaMuscla
Executive Summary
Lupin’s rare disease drug, NaMuscla, has been recommended for marketing authorization in Europe – a key milestone for the firm as it shapes its play in the specialty segment. The company may consider taking NaMuscla to other markets such as Japan as well and also add assets to its neuroscience portfolio.
You may also be interested in...
Asia Deal Watch: Lupin Signs Up Three EU Marketing Partners For NaMuscla
Lupin links with Exeltis, Cresco and Macure to sell the NDM therapy in western and central Europe. Plus deals involving Cipla, GoApptiv, Takeda, Debiopharm, PharmaMar and TTY.
Controversial Dengue Drug Among Six Products To Get EMA Thumbs Up
Dengvaxia, the dengue vaccine from Sanofi that was suspended in the Philippines last year, is among six new products to get a recommendation for marketing authorization from the European Medicines Agency this week.
Lupin Primes For Specialty Future With Symbiomix Acquisition
Lupin has snapped up Symbiomix Therapeutics in the US as it evolves its business from a predominantly straight-generics play to a model with an increasing mix of complex generics, specialty medicines and biosimilars. The latest deal gives Lupin access to a therapy in the women’s health segment recently approved by the US FDA.